1
KSA ASTHMA Actual Exam 2026/2027: Questions
with Correct Verified Answers | Updated | Guaranteed
Success for Saudi Commission Certification – Pass
Guaranteed - A+ Graded
Section 1: Asthma Pathophysiology (10 Questions)
Q1: Which inflammatory cell type is most characteristic of T2-high asthma endotype and is
targeted by anti-IL-5/IL-5R biologic therapies?
A. Neutrophils
B. Eosinophils [CORRECT]
C. Macrophages
D. Basophils
Correct Answer: B
Rationale: T2-high asthma is characterized by type 2 inflammation driven by IL-4, IL-5, and IL-
13, resulting in eosinophilic airway inflammation. Eosinophils are the primary target of anti-IL-5
therapies (mepolizumab, reslizumab) and anti-IL-5R therapy (benralizumab). T2-low asthma
typically shows neutrophilic or paucigranulocytic inflammation. [GINA 2026; CHEST 2026
Biologic Guidelines]
Q2: A 34-year-old patient with allergic asthma experiences bronchoconstriction after taking
aspirin. Which pathophysiological mechanism explains this reaction?
A. Beta-blockade of bronchial smooth muscle
B. Inhibition of cyclooxygenase-1 leading to increased cysteinyl leukotriene production
[CORRECT]
C. IgE-mediated mast cell degranulation
D. Direct histamine release from basophils
Correct Answer: B
Rationale: Aspirin-exacerbated respiratory disease (AERD) results from inhibition of COX-1,
which shunts arachidonic acid metabolism toward the 5-lipoxygenase pathway, increasing
cysteinyl leukotrienes (C4, D4, E4) that cause bronchoconstriction and mucus secretion. This is
not an IgE-mediated allergy but a pharmacological effect. Leukotriene receptor antagonists
,2
(montelukast) or 5-lipoxygenase inhibitors are therapeutic options. [GINA 2026; AERD
Pathophysiology]
Q3: Which pathophysiological process best explains airway remodeling in long-standing
asthma?
A. Acute bronchospasm reversible with bronchodilators
B. Chronic inflammation leading to subepithelial fibrosis, smooth muscle hypertrophy, and
basement membrane thickening [CORRECT]
C. Acute viral infection of bronchial epithelium
D. Immediate hypersensitivity reaction only
Correct Answer: B
Rationale: Airway remodeling refers to structural changes from chronic inflammation:
subepithelial fibrosis (collagen deposition), smooth muscle hypertrophy/hyperplasia, basement
membrane thickening, and mucous gland hyperplasia. These changes can lead to fixed airflow
limitation, particularly in long-standing severe asthma or late-onset asthma phenotypes. Unlike
acute bronchospasm, remodeling is only partially reversible. [GINA 2026; Airway Remodeling]
Q4: In exercise-induced bronchoconstriction (EIB), what is the primary physiological trigger for
airway narrowing?
A. Allergen exposure during physical activity
B. Heat and water loss from airway surfaces causing osmotic and thermal changes [CORRECT]
C. Lactic acid accumulation in respiratory muscles
D. Increased cardiac output compressing airways
Correct Answer: B
Rationale: EIB is triggered by hyperventilation during exercise, leading to evaporative water loss
and heat transfer from airway surfaces. This increases osmolarity of the airway lining fluid,
triggering mast cell and inflammatory mediator release (histamine, leukotrienes, prostaglandins).
The "osmotic theory" and "thermal theory" explain this response. Pre-treatment with SABA or
ICS-formoterol 15 minutes before exercise is recommended. [GINA 2026; EIB Pathophysiology]
Q5: Which cytokine is blocked by tezepelumab, making it effective in both T2-high and T2-low
asthma phenotypes?
A. Interleukin-4 (IL-4)
B. Interleukin-5 (IL-5)
, 3
C. Thymic stromal lymphopoietin (TSLP) [CORRECT]
D. Interleukin-13 (IL-13)
Correct Answer: C
Rationale: Tezepelumab is a human monoclonal antibody that blocks TSLP, an epithelial cell-
derived cytokine that acts upstream of the inflammatory cascade. Unlike other biologics that
target specific T2 cytokines (IL-4, IL-5, IL-13), TSLP inhibition affects both T2-high and T2-low
pathways, making tezepelumab effective regardless of baseline eosinophil count or FeNO levels.
[CHEST 2026 Biologic Guidelines; GINA 2026]
Q6: A patient with obesity presents with late-onset asthma that is difficult to control. Which
pathophysiological mechanism likely contributes to this phenotype?
A. Increased IgE-mediated allergic inflammation only
B. Mechanical restriction and systemic inflammation with altered lung mechanics [CORRECT]
C. Purely psychogenic airway constriction
D. Excessive eosinophilic inflammation requiring anti-IL-5 therapy
Correct Answer: B
Rationale: Obesity-associated asthma represents a distinct phenotype characterized by reduced
lung volumes, mechanical effects on airway stretch, and systemic inflammation (elevated IL-6,
TNF-α, leptin) rather than classic T2 eosinophilic inflammation. These patients often have less
eosinophilia and may respond less well to ICS. Weight reduction and non-T2 targeted therapies
may be more beneficial. [GINA 2026; Asthma Phenotypes]
Q7: Which genetic factor is most strongly associated with the development of allergic asthma?
A. Alpha-1 antitrypsin deficiency
B. Atopy and elevated total IgE with specific gene variants (e.g., IL-4, IL-13, FCER1B)
[CORRECT]
C. Cystic fibrosis transmembrane conductance regulator (CFTR) mutations
D. Surfactant protein B deficiency
Correct Answer: B
Rationale: Atopy (genetic predisposition to produce IgE against allergens) is the strongest
identifiable predisposing factor for asthma. Multiple genes involved in T2 inflammation (IL-4,
IL-13, STAT6, FCER1B) and innate immunity (ORMDL3, GSDMB) are associated with asthma
risk. These genetic factors interact with environmental exposures (epigenetics) to determine
disease expression. [GINA 2026; Asthma Genetics]
KSA ASTHMA Actual Exam 2026/2027: Questions
with Correct Verified Answers | Updated | Guaranteed
Success for Saudi Commission Certification – Pass
Guaranteed - A+ Graded
Section 1: Asthma Pathophysiology (10 Questions)
Q1: Which inflammatory cell type is most characteristic of T2-high asthma endotype and is
targeted by anti-IL-5/IL-5R biologic therapies?
A. Neutrophils
B. Eosinophils [CORRECT]
C. Macrophages
D. Basophils
Correct Answer: B
Rationale: T2-high asthma is characterized by type 2 inflammation driven by IL-4, IL-5, and IL-
13, resulting in eosinophilic airway inflammation. Eosinophils are the primary target of anti-IL-5
therapies (mepolizumab, reslizumab) and anti-IL-5R therapy (benralizumab). T2-low asthma
typically shows neutrophilic or paucigranulocytic inflammation. [GINA 2026; CHEST 2026
Biologic Guidelines]
Q2: A 34-year-old patient with allergic asthma experiences bronchoconstriction after taking
aspirin. Which pathophysiological mechanism explains this reaction?
A. Beta-blockade of bronchial smooth muscle
B. Inhibition of cyclooxygenase-1 leading to increased cysteinyl leukotriene production
[CORRECT]
C. IgE-mediated mast cell degranulation
D. Direct histamine release from basophils
Correct Answer: B
Rationale: Aspirin-exacerbated respiratory disease (AERD) results from inhibition of COX-1,
which shunts arachidonic acid metabolism toward the 5-lipoxygenase pathway, increasing
cysteinyl leukotrienes (C4, D4, E4) that cause bronchoconstriction and mucus secretion. This is
not an IgE-mediated allergy but a pharmacological effect. Leukotriene receptor antagonists
,2
(montelukast) or 5-lipoxygenase inhibitors are therapeutic options. [GINA 2026; AERD
Pathophysiology]
Q3: Which pathophysiological process best explains airway remodeling in long-standing
asthma?
A. Acute bronchospasm reversible with bronchodilators
B. Chronic inflammation leading to subepithelial fibrosis, smooth muscle hypertrophy, and
basement membrane thickening [CORRECT]
C. Acute viral infection of bronchial epithelium
D. Immediate hypersensitivity reaction only
Correct Answer: B
Rationale: Airway remodeling refers to structural changes from chronic inflammation:
subepithelial fibrosis (collagen deposition), smooth muscle hypertrophy/hyperplasia, basement
membrane thickening, and mucous gland hyperplasia. These changes can lead to fixed airflow
limitation, particularly in long-standing severe asthma or late-onset asthma phenotypes. Unlike
acute bronchospasm, remodeling is only partially reversible. [GINA 2026; Airway Remodeling]
Q4: In exercise-induced bronchoconstriction (EIB), what is the primary physiological trigger for
airway narrowing?
A. Allergen exposure during physical activity
B. Heat and water loss from airway surfaces causing osmotic and thermal changes [CORRECT]
C. Lactic acid accumulation in respiratory muscles
D. Increased cardiac output compressing airways
Correct Answer: B
Rationale: EIB is triggered by hyperventilation during exercise, leading to evaporative water loss
and heat transfer from airway surfaces. This increases osmolarity of the airway lining fluid,
triggering mast cell and inflammatory mediator release (histamine, leukotrienes, prostaglandins).
The "osmotic theory" and "thermal theory" explain this response. Pre-treatment with SABA or
ICS-formoterol 15 minutes before exercise is recommended. [GINA 2026; EIB Pathophysiology]
Q5: Which cytokine is blocked by tezepelumab, making it effective in both T2-high and T2-low
asthma phenotypes?
A. Interleukin-4 (IL-4)
B. Interleukin-5 (IL-5)
, 3
C. Thymic stromal lymphopoietin (TSLP) [CORRECT]
D. Interleukin-13 (IL-13)
Correct Answer: C
Rationale: Tezepelumab is a human monoclonal antibody that blocks TSLP, an epithelial cell-
derived cytokine that acts upstream of the inflammatory cascade. Unlike other biologics that
target specific T2 cytokines (IL-4, IL-5, IL-13), TSLP inhibition affects both T2-high and T2-low
pathways, making tezepelumab effective regardless of baseline eosinophil count or FeNO levels.
[CHEST 2026 Biologic Guidelines; GINA 2026]
Q6: A patient with obesity presents with late-onset asthma that is difficult to control. Which
pathophysiological mechanism likely contributes to this phenotype?
A. Increased IgE-mediated allergic inflammation only
B. Mechanical restriction and systemic inflammation with altered lung mechanics [CORRECT]
C. Purely psychogenic airway constriction
D. Excessive eosinophilic inflammation requiring anti-IL-5 therapy
Correct Answer: B
Rationale: Obesity-associated asthma represents a distinct phenotype characterized by reduced
lung volumes, mechanical effects on airway stretch, and systemic inflammation (elevated IL-6,
TNF-α, leptin) rather than classic T2 eosinophilic inflammation. These patients often have less
eosinophilia and may respond less well to ICS. Weight reduction and non-T2 targeted therapies
may be more beneficial. [GINA 2026; Asthma Phenotypes]
Q7: Which genetic factor is most strongly associated with the development of allergic asthma?
A. Alpha-1 antitrypsin deficiency
B. Atopy and elevated total IgE with specific gene variants (e.g., IL-4, IL-13, FCER1B)
[CORRECT]
C. Cystic fibrosis transmembrane conductance regulator (CFTR) mutations
D. Surfactant protein B deficiency
Correct Answer: B
Rationale: Atopy (genetic predisposition to produce IgE against allergens) is the strongest
identifiable predisposing factor for asthma. Multiple genes involved in T2 inflammation (IL-4,
IL-13, STAT6, FCER1B) and innate immunity (ORMDL3, GSDMB) are associated with asthma
risk. These genetic factors interact with environmental exposures (epigenetics) to determine
disease expression. [GINA 2026; Asthma Genetics]
